Insider Actions for Alkermes PLC
02/21/2021 |
Richard F. Pops Director and CEO, Alkermes plc; Director |
14,386 | Derivative/Non-derivative trans. at $19.58 per share. | 281,677 |
02/21/2021 |
Michael J. Landine SVP, Corp Dev., Alkermes, Inc. |
2,587 | Derivative/Non-derivative trans. at $19.58 per share. | 50,653 |
02/21/2021 |
David Jose Gaffin SVP, CLO, Alkermes, Inc. |
2,022 | Derivative/Non-derivative trans. at $19.58 per share. | 39,590 |
02/21/2021 |
Blair C. Jackson EVP, Chief Operating Officer |
1,412 | Derivative/Non-derivative trans. at $19.58 per share. | 27,646 |
02/21/2021 |
Iain Michael Brown SVP, Chief Financial Officer |
1,412 | Derivative/Non-derivative trans. at $19.58 per share. | 27,646 |
02/21/2021 |
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
2,022 | Derivative/Non-derivative trans. at $19.58 per share. | 39,590 |
02/21/2021 |
Richard F. Pops Director and CEO, Alkermes plc; Director |
32,400 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/21/2021 |
David Jose Gaffin SVP, CLO, Alkermes, Inc. |
6,875 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/21/2021 |
Blair C. Jackson EVP, Chief Operating Officer |
4,800 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/21/2021 |
Iain Michael Brown SVP, Chief Financial Officer |
4,800 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/21/2021 |
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
6,875 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/20/2021 |
Michael J. Landine SVP, Corp Dev., Alkermes, Inc. |
5,825 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/20/2021 |
Michael J. Landine SVP, Corp Dev., Alkermes, Inc. |
5,353 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/20/2021 |
David Jose Gaffin SVP, CLO, Alkermes, Inc. |
7,036 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/20/2021 |
Blair C. Jackson EVP, Chief Operating Officer |
4,589 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/20/2021 |
Iain Michael Brown SVP, Chief Financial Officer |
4,589 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/20/2021 |
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
10,095 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/20/2021 |
C. Todd Nichols SVP, Chief Commercial Officer |
3,824 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/20/2021 |
Michael J. Landine SVP, Corp Dev., Alkermes, Inc. |
2,360 | Derivative/Non-derivative trans. at $19.58 per share. | 46,208 |
02/20/2021 |
David Jose Gaffin SVP, CLO, Alkermes, Inc. |
2,061 | Derivative/Non-derivative trans. at $19.58 per share. | 40,354 |
02/20/2021 |
Blair C. Jackson EVP, Chief Operating Officer |
1,374 | Derivative/Non-derivative trans. at $19.58 per share. | 26,902 |
02/20/2021 |
Iain Michael Brown SVP, Chief Financial Officer |
1,378 | Derivative/Non-derivative trans. at $19.58 per share. | 26,981 |
02/20/2021 |
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
3,064 | Derivative/Non-derivative trans. at $19.58 per share. | 59,993 |
02/20/2021 |
C. Todd Nichols SVP, Chief Commercial Officer |
1,292 | Derivative/Non-derivative trans. at $19.58 per share. | 25,297 |
02/17/2021 |
Richard F. Pops Director and CEO, Alkermes plc; Director |
3,869 | Derivative/Non-derivative trans. at $19.97 per share. | 77,263 |
02/17/2021 |
Michael J. Landine SVP, Corp Dev., Alkermes, Inc. |
1,492 | Derivative/Non-derivative trans. at $19.97 per share. | 29,795 |
02/17/2021 |
David Jose Gaffin SVP, CLO, Alkermes, Inc. |
868 | Derivative/Non-derivative trans. at $19.97 per share. | 17,333 |
02/17/2021 |
Blair C. Jackson EVP, Chief Operating Officer |
781 | Derivative/Non-derivative trans. at $19.97 per share. | 15,596 |
02/17/2021 |
Iain Michael Brown SVP, Chief Financial Officer |
868 | Derivative/Non-derivative trans. at $19.97 per share. | 17,333 |
02/17/2021 |
Richard F. Pops Director and CEO, Alkermes plc; Director |
8,750 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/17/2021 |
Michael J. Landine SVP, Corp Dev., Alkermes, Inc. |
3,000 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/17/2021 |
David Jose Gaffin SVP, CLO, Alkermes, Inc. |
2,500 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/17/2021 |
Blair C. Jackson EVP, Chief Operating Officer |
2,250 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/17/2021 |
Iain Michael Brown SVP, Chief Financial Officer |
2,500 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/16/2021 |
Richard F. Pops Director and CEO, Alkermes plc; Director |
8,074 | Derivative/Non-derivative trans. at $19.79 per share. | 159,784 |
02/16/2021 |
Michael J. Landine SVP, Corp Dev., Alkermes, Inc. |
1,678 | Derivative/Non-derivative trans. at $19.79 per share. | 33,207 |
02/16/2021 |
David Jose Gaffin SVP, CLO, Alkermes, Inc. |
1,172 | Derivative/Non-derivative trans. at $19.79 per share. | 23,193 |
02/16/2021 |
Blair C. Jackson EVP, Chief Operating Officer |
825 | Derivative/Non-derivative trans. at $19.79 per share. | 16,326 |
02/16/2021 |
Iain Michael Brown SVP, Chief Financial Officer |
825 | Derivative/Non-derivative trans. at $19.79 per share. | 16,326 |
02/16/2021 |
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
1,172 | Derivative/Non-derivative trans. at $19.79 per share. | 23,193 |
02/16/2021 |
Richard F. Pops Director and CEO, Alkermes plc; Director |
18,125 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/16/2021 |
Michael J. Landine SVP, Corp Dev., Alkermes, Inc. |
3,375 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/16/2021 |
David Jose Gaffin SVP, CLO, Alkermes, Inc. |
3,375 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/16/2021 |
Blair C. Jackson EVP, Chief Operating Officer |
2,375 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/16/2021 |
Iain Michael Brown SVP, Chief Financial Officer |
2,375 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/16/2021 |
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
3,375 | Derivative/Non-derivative trans. at $0 per share. | 0 |
01/13/2021 |
Wendy L. Dixon Director |
20,000 | Derivative/Non-derivative trans. at $12.62 per share. | 252,400 |
01/13/2021 |
Wendy L. Dixon Director |
15,000 | Derivative/Non-derivative trans. at $12.62 per share. | 189,300 |
10/01/2020 |
Paul J. Mitchell Director |
20,000 | Disposition at $16.61 per share. | 332,200 |
10/01/2020 |
Paul J. Mitchell Director |
20,000 | Derivative/Non-derivative trans. at $14.92 per share. | 298,400 |
09/28/2020 |
David Westbrook Anstice Director |
17,832 | Disposition at $16.78 per share. | 299,220 |
09/28/2020 |
David Westbrook Anstice Director |
20,000 | Derivative/Non-derivative trans. at $14.92 per share. | 298,400 |
07/14/2020 |
Michael J. Landine SVP, Corp Dev., Alkermes, Inc. |
5,523 | Derivative/Non-derivative trans. at $18.1 per share. | 99,966 |
06/07/2020 |
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
368 | Derivative/Non-derivative trans. at $17.19 per share. | 6,325 |
06/07/2020 |
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
1,250 | Derivative/Non-derivative trans. at $0 per share. | 0 |
06/05/2020 |
David Jose Gaffin SVP, CLO, Alkermes, Inc. |
1,000 | Gift at $0 per share. | 0 |
06/05/2020 |
C. Todd Nichols SVP, Chief Commercial Officer |
1,029 | Derivative/Non-derivative trans. at $17.19 per share. | 17,688 |
06/05/2020 |
C. Todd Nichols SVP, Chief Commercial Officer |
3,500 | Derivative/Non-derivative trans. at $0 per share. | 0 |